Zacks Investment Research cut shares of Halyard Health (NYSE:HYH) from a buy rating to a hold rating in a research report sent to investors on Thursday morning.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

A number of other research firms also recently commented on HYH. ValuEngine raised shares of Halyard Health from a hold rating to a buy rating in a report on Saturday, November 4th. TheStreet downgraded shares of Halyard Health from a b- rating to a c+ rating in a report on Monday, October 30th. KeyCorp reissued a hold rating on shares of Halyard Health in a report on Tuesday, October 17th. Finally, Stifel Nicolaus reissued a buy rating and set a $52.00 price objective on shares of Halyard Health in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $49.00.

Shares of Halyard Health (HYH) traded down $0.15 during trading hours on Thursday, hitting $48.77. 30,176 shares of the stock traded hands, compared to its average volume of 297,754. The stock has a market capitalization of $2,290.00, a P/E ratio of 41.11, a price-to-earnings-growth ratio of 2.56 and a beta of 1.71. The company has a current ratio of 2.13, a quick ratio of 1.19 and a debt-to-equity ratio of 0.49. Halyard Health has a 1-year low of $35.24 and a 1-year high of $50.99.

Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.13. The business had revenue of $401.40 million for the quarter, compared to the consensus estimate of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.48 earnings per share. sell-side analysts forecast that Halyard Health will post 2.08 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Riverhead Capital Management LLC boosted its holdings in Halyard Health by 88.1% during the second quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 1,497 shares in the last quarter. Jarislowsky Fraser Ltd purchased a new stake in Halyard Health during the third quarter worth about $200,000. Quotient Investors LLC purchased a new stake in Halyard Health during the third quarter worth about $203,000. Jane Street Group LLC purchased a new stake in Halyard Health during the third quarter worth about $211,000. Finally, QS Investors LLC boosted its holdings in Halyard Health by 305.6% during the second quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock worth $203,000 after buying an additional 3,900 shares in the last quarter. 89.32% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/halyard-health-hyh-downgraded-by-zacks-investment-research-to-hold/1840004.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Get a free copy of the Zacks research report on Halyard Health (HYH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.